In their treatment algorithm, Stage IVB and IVC ATCs receive neoadjuvant BRAF and MEK inhibitors with or without immunotherapy, and surgery is performed if the tumor is considered to be resectable.31 The gene discussed is BRAF; the disease is Ehlers-Danlos syndrome, musculocontractural type.